Syndyma 100 mg Injection
  1. Home
  2. Pharma Products
  3. Cipla Ltd
  4. Syndyma 100 mg Injection

Syndyma 100 mg Injection

Syndyma 100 mg Injection contains bevacizumab 100 mg, a monoclonal antibody used for several types of cancer. It is administered by intravenous infusion under the supervision of a healthcare professional. Bevacizumab blocks vascular endothelial growth factor (VEGF), helping inhibit the formation of new blood vessels that support tumor growth.

BUY NOW

Category

Syndyma 100 mg Injection is used in conditions including metastatic colorectal cancer, non-small cell lung cancer, kidney cancer, ovarian cancer, cervical cancer, and certain other advanced cancers. Bevacizumab belongs to the VEGF inhibitor class and works by reducing tumor blood-vessel formation. The dose and treatment schedule are determined by the treating oncologist according to the cancer type and treatment protocol. The medicine requires appropriate medical monitoring during treatment because it can cause clinically significant adverse effects.

Technical Specification

Specification Details
Active Ingredient Bevacizumab
Strength 100 mg
Dosage Form Injection / Concentrate for Infusion
Route of Administration Intravenous Infusion
Pack Size 4 mL in 1 Vial
Manufacturer/Marketer Cipla Ltd.

Product Also Known As

Syndyma 100 mg Injection, Syndyma 100 Injection, Syndyma Bevacizumab Injection, Bevacizumab 100 mg Injection, Bevacizumab 100 mg/4 mL Injection, Bevacizumab Anti-VEGF Injection